Cellectar Biosciences Inc (NAS:CLRB)

$ 2.87 0.01 (0.35%) Market Cap: 102.89 Mil Enterprise Value: 80.48 Mil PE Ratio: 0 PB Ratio: 10.63 GF Score: 38/100

Q1 2024 Cellectar Biosciences Inc Earnings Call Transcript
May 14, 2024

$3.18 (+3.92%)

Earnings
Q4 2023 Cellectar Biosciences Inc Earnings Call Transcript
Mar 27, 2024

$3.64 (-5.58%)

Earnings
Cellectar Biosciences Inc KOL Call Transcript
Jan 19, 2024
Cellectar Biosciences Inc at EBD Group Biotech Showcase Transcript
Jan 09, 2024
Cellectar Biosciences Inc Top-line Data Call Transcript
Jan 08, 2024
Q3 2023 Cellectar Biosciences Inc Earnings Call Transcript
Nov 02, 2023

$2.4 (+0.84%)

Earnings
Cellectar Biosciences Inc Annual Shareholders Meeting Transcript
Jun 23, 2023
Cellectar Biosciences Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Cellectar Biosciences Inc at ROTH Conference Transcript
Mar 13, 2023
Cellectar Biosciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021
Cellectar Biosciences Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Cellectar Biosciences Inc at Next Generation Targeted Cancer Therapies - The Cellectar Story! Transcript
Oct 16, 2020

Q3 2023 Cellectar Biosciences Inc Earnings Call Transcript

Nov 02, 2023 / 12:30PM GMT

Release Date Price: $2.4 (+0.84%)

Transcript 10-Q8-K

Operator

Good morning, and welcome to Cellectar Biosciences' third-quarter 2023 update call. Today's conference is being recorded. At this time, I would like to turn the conference over to Monique Kosse of LifeSci Advisors. Please go ahead.

Monique Kosse

LifeSci Advisors, LLC - IR

Thank you, operator, and welcome, everyone. This morning, Cellectar issued a press release providing a corporate update. You may access that release on the company's website under the Investors tab.

With us today are Jim Caruso, President and CEO of Cellectar; Chad Kolean, Chief Financial Officer; Jarrod Longcor, Chief Operating Officer; Shane Lea, Chief Commercial Officer; and Andrei Shustov, VP, Medical. Following our prepared remarks, we will open the call for a Q&A session.

Before we begin, I would like to remind everyone that statements made during this call, including the Q&A session relating to Cellectar's expected future performance, future business prospects, or future events or plans are forward-looking statements as defined under the Private Securities

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.